Bristol Myers Squibb (BMY) Other Operating Expenses (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Other Operating Expenses for 18 consecutive years, with $4.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Operating Expenses fell 33.87% year-over-year to $4.1 billion in Q2 2026; TTM through Jun 2026 was $19.1 billion, a 17.81% decrease from a year earlier, with the FY2025 full-year figure at $21.6 billion, down 41.66% from the prior year.
• Other Operating Expenses was $4.1 billion for Q2 2026 at Bristol Myers Squibb, up from $4.0 billion in the prior quarter.
• Over five years, Other Operating Expenses peaked at $18.3 billion in Q1 2024 and troughed at $4.0 billion in Q1 2026.
• A 5-year average of $6.0 billion and a median of $5.2 billion in 2023 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses jumped 308.54% in 2024 and tumbled 76.04% in 2025, its largest moves.
• Over 5 years, Other Operating Expenses stood at $4.8 billion in 2022, then grew by 10.08% to $5.3 billion in 2023, then surged by 30.24% to $6.8 billion in 2024, then retreated by 8.41% to $6.3 billion in 2025, then slumped by 34.53% to $4.1 billion in 2026.
• The last three Other Operating Expenses figures came in at $4.1 billion (Q2 2026), $4.0 billion (Q1 2026), and $6.3 billion (Q4 2025), per Business Quant data.